文献速递前列腺癌

前列腺癌单侧盆腔淋巴结清扫列线图的外部验证

External validation of a nomogram for unilateral pelvic lymph node dissection in prostate cancer.
PubMed 文献 · BJU Int · 2025-02-20

在406例接受双侧扩大盆腔淋巴结清扫的前列腺癌患者中,外部验证单侧清扫列线图(unilat-NG)并与Briganti 2019列线图比较对侧淋巴结侵犯的预测性能。Briganti 2019列线图AUC为0.72,优于unilat-NG各截断值(AUC 0.58–0.69);unilat-NG 2.5%截断值可省略74.6%患者对侧清扫,但2.5%患者pN0被误分类。作者认为如指示行盆腔淋巴结清扫,双侧清扫仍应为标准治疗。

要点

  • Briganti 2019列线图预测对侧淋巴结侵犯AUC 0.72,优于unilat-NG。
  • unilat-NG 2.5%截断值可省略303/406(74.6%)患者对侧清扫,误分类10/406(2.5%)pN0患者。
  • 作者结论:如指示行盆腔淋巴结清扫,双侧扩大清扫仍应为标准治疗。

核心结论

  • Briganti 2019列线图在对侧淋巴结侵犯预测上优于新型unilat-NG列线图。
  • 使用任一列线图,相当比例接受单侧扩大盆腔淋巴结清扫的患者会被误分类为pN0。
  • 因此,如指示行盆腔淋巴结清扫,双侧扩大盆腔淋巴结清扫仍应为标准治疗。

研究设计与样本

  • 在机构数据库内识别接受磁共振成像融合活检并连续行双侧扩大盆腔淋巴结清扫的前列腺癌患者。
  • 共纳入406例连续患者。
  • 主要终点为与前列腺 adverse 癌特征对侧的淋巴结侵犯检出率。

主要发现

  • 406例中68例(16.7%)在根治性前列腺切除术时病理(p)N1。
  • Briganti 2019列线图在7%截断值的AUC为0.72(95%CI 0.66-0.78)。
  • 应用unilat-NG 2.5%截断值,303/406(74.6%)患者可省略对侧扩大盆腔淋巴结清扫,误分类10/406(2.5%)pN0患者。

关键数值与推荐

  • unilat-NG 1%截断值AUC 0.58(95%CI 0.53-0.63)。
  • unilat-NG 2%截断值AUC 0.67(95%CI 0.59-0.75)。
  • Briganti 2019列线图7%截断值AUC 0.72(95%CI 0.66-0.78)。

临床怎么用

  • 作者结论认为如指示行盆腔淋巴结清扫,双侧扩大盆腔淋巴结清扫仍应为标准治疗。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore the rationale of unilateral extended pelvic lymph node dissection (ePLND) during radical prostatectomy (RP) by external validation of a nomogram for unilateral ePLND (unilat-NG) and comparison to the Briganti 2019 nomogram. PATIENTS AND METHODS: Patients with magnetic resonance imaging-fusion biopsy and consecutive RP with bilateral ePLND were identified within an institutional database. The primary endpoint was the detection rate of lymph node invasion (LNI) contralateral to the prostatic lobe with adverse cancer characteristics. The performance of the unilat-NG and the Briganti 2019 nomogram to detect contralateral LNI was assessed using descriptive analysis, the receiver operating characteristic curve-derived area under the curve (AUC), and multivariable logistic regression analyses. RESULTS: Of the overall 406 consecutive patients, 68/406 (16.7%) presented with pathological (p)N1 disease at RP. The AUC for the unilat-NG with a 1%, 2% and 2.5% cut-off was 0.58 (95% confidence interval [CI] 0.53-0.63), 0.67 (95% CI 0.59-0.75), and 0.69 (95% CI 0.60-0. 77), respectively; compared to an AUC of 0.72 (95% CI 0.66-0.78) for the Briganti 2019 nomogram with a 7% cut-off. Applying the unilat-NG with a 2.5% cut-off, contralateral ePLND could be omitted in 303/406 (74.6%) patients, misclassifying 10/406 (2.5%) patients with pN0 disease. CONCLUSION: The Briganti 2019 nomogram outperformed the novel unilat-NG in contralateral LNI prediction. Yet, a significant proportion of patients undergoing unilateral ePLND would be falsely classified with pN0 disease using any of the nomograms. Therefore, bilateral ePLND should remain the standard of care if PLND is indicated.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ortner G, Falkenbach F, Kachanov M, et al. External validation of a nomogram for unilateral pelvic lymph node dissection in prostate cancer. BJU Int. 2025. PMID: 39979125. doi:10.1111/bju.16687

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。